ValuEngine cut shares of icad inc. (NASDAQ:ICAD) from a sell rating to a strong sell rating in a report released on Thursday.

Separately, Laidlaw reaffirmed a buy rating and set a $11.00 price objective on shares of icad inc. in a research note on Tuesday, July 25th.

Shares of icad inc. (NASDAQ:ICAD) traded down 2.0698% on Thursday, reaching $3.7899. The company’s stock had a trading volume of 10,511 shares. icad inc. has a 12 month low of $2.82 and a 12 month high of $6.15. The firm’s market cap is $62.89 million. The stock has a 50 day moving average of $3.78 and a 200-day moving average of $4.34.

icad inc. (NASDAQ:ICAD) last announced its quarterly earnings data on Tuesday, August 8th. The technology company reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.03. icad inc. had a negative return on equity of 44.39% and a negative net margin of 34.74%. The firm had revenue of $6.41 million for the quarter, compared to analysts’ expectations of $6.41 million. On average, analysts anticipate that icad inc. will post ($0.54) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This news story was originally published by Daily Political and is the property of of Daily Political. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/09/08/icad-inc-icad-downgraded-by-valuengine-to-strong-sell.html.

In related news, Director Dr Lawrence Howard acquired 10,000 shares of icad inc. stock in a transaction dated Wednesday, August 23rd. The shares were purchased at an average cost of $3.33 per share, with a total value of $33,300.00. Following the completion of the purchase, the director now owns 488,022 shares of the company’s stock, valued at $1,625,113.26. The transaction was disclosed in a document filed with the SEC, which is available through this link. 19.10% of the stock is currently owned by company insiders.

Several large investors have recently made changes to their positions in ICAD. Essex Investment Management Co. LLC grew its stake in shares of icad inc. by 822.3% during the second quarter. Essex Investment Management Co. LLC now owns 139,766 shares of the technology company’s stock valued at $586,000 after buying an additional 124,612 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of icad inc. by 0.4% during the second quarter. Vanguard Group Inc. now owns 456,377 shares of the technology company’s stock valued at $1,912,000 after buying an additional 2,007 shares during the last quarter. Finally, Argent Capital Management LLC grew its stake in shares of icad inc. by 13.2% during the second quarter. Argent Capital Management LLC now owns 713,650 shares of the technology company’s stock valued at $2,990,000 after buying an additional 82,967 shares during the last quarter. 23.74% of the stock is currently owned by hedge funds and other institutional investors.

icad inc. Company Profile

iCAD, Inc is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The Company provides image analysis and clinical decision support solutions for mammography, Magnetic Resonance Imaging and Computed Tomography imaging. It operates in two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy).

Receive News & Ratings for icad inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for icad inc. and related companies with MarketBeat.com's FREE daily email newsletter.